 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: LEMTRADA (Campath, alemtuzumab) |
|
***************************************************** |
|
#Post#: 4521-------------------------------------------------- |
|
(Abst.) Siponimod following alemtuzumab for SPMS... |
|
By: agate Date: August 18, 2024, 3:36 pm |
|
--------------------------------------------------------- |
|
From PubMed (August 18, 2024)--"Siponimod following alemtuzumab |
|
for secondary progressive multiple sclerosis: Investigating |
|
sequential therapy--a case series": |
|
https://pubmed.ncbi.nlm.nih.gov/39151236/ |
|
[quote]The prescription of subsequent therapies following |
|
Alemtuzumab, as mandated by label guidance for a treatment-free |
|
period of at least 5 years, presents a complex challenge, |
|
particularly if there is concurrent conversion to secondary |
|
progressive disease course. [/quote] |
|
That 5-year wait before starting another MS treatment after |
|
stopping alemtuzumab would probably be a drawback for many |
|
patients. |
|
***************************************************** |
